BioCentury | Aug 17, 2015
Finance

Medigene remade

Within 18 months, Medigene AG has used a small acquisition to gain a new, predominantly institutional shareholder base that has infused the German company with enough cash to pursue three platforms in parallel. Management says...
BC Extra | Oct 29, 2014
Financial News

SynCore raises $19.4M in Taiwanese IPO

SynCore Biotechnology Co. Ltd. (GreTai-E:4192) lost NT$15.90 (18%) to NT$70.10 in its first day of trading Tuesday after raising NT$590.6 million ($19.4 million) through the sale of 6.8 million shares at NT$86 in an IPO...
BC Week In Review | Jun 24, 2013
Clinical News

EndoTAG-1: Final Phase II data

Final data from an investigator-initiated Phase II trial in 15 patients with non-metastatic HER2-negative breast cancer showed that once-weekly 22 mg/m 2 EndoTAG-1 plus 70 mg/m 2 paclitaxel as neoadjuvant therapy led to a reduction...
BC Week In Review | Jun 10, 2013
Company News

Medigene, Sinphar Pharmaceutical deal

Medigene and Sinphar's SynCore Biotechnology Co. Ltd. subsidiary amended a 2012 deal to give SynCore worldwide commercialization rights to EndoTAG-1 . SynCore previously had rights to EndoTAG-1 in Asia, Australia and New Zealand. SynCore will fund...
BC Week In Review | Jul 16, 2012
Company News

Medigene, Sinphar Pharmaceutical deal

Medigene granted Sinphar's SynCore Biotechnology Co. Ltd. subsidiary exclusive rights to co-develop and commercialize EndoTAG-1 in Asia, Australia and New Zealand. SynCore will fund the Asian portion of the planned international Phase III trial to...
BC Week In Review | Jun 11, 2012
Company News

Medigene, Cowen Healthcare Royalty Partners L.P. deal

MediGene sold Cowen Healthcare Royalty Partners a 2% royalty on European sales of Eligard leuprolide for $17.7 million in cash. The royalty comes from MediGene's 2010 deal that gave Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan)...
BC Extra | Jun 8, 2012
Company News

MediGene sells Eligard royalties

MediGene AG (Xetra:MDG) sold Cowen Healthcare Royalty Partners a 2% royalty on European sales of Eligard leuprolide for $17.7 million in cash. The royalty comes from MediGene's 2010 deal that gave Astellas Pharma Inc. (Tokyo:4503)...
BC Week In Review | Dec 12, 2011
Clinical News

EndoTAG-1: Additional Phase II data

Additional data from an open-label, active-controlled, international Phase II trial in 133 evaluable TNBC patients showed that once-weekly 22 mg/m 2 EndoTAG-1 plus 70 mg/m 2 paclitaxel led to a median OS of 13 months...
BC Extra | Dec 10, 2011
Clinical News

MediGene reports OS data for EndoTAG-1

MediGene AG (Xetra:MDG) reported additional data from a Phase II trial of EndoTAG-1 to treat triple-negative breast cancer (TNBC). Once-weekly EndoTAG-1 plus paclitaxel led to a median overall survival of 13 months vs. 11.9 months...
BioCentury | Jul 11, 2011
Regulation

Looking beyond Avastin

As clinicians reduce their use of Avastin bevacizumab for metastatic breast cancer, they are looking hopefully toward the more than 24 targeted therapies in Phase II or Phase III trials for metastatic HER2-negative breast cancer....
Items per page:
1 - 10 of 53